UBX domain protein 4Genealiases: UBXD2 · UBXDC1 · erasin
Q-omics provides the consensus-scored UBXN4 profile across patient tissues and cancer cell-line models. UBXN4 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, UBXN4 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, UBXN4 RNA expression shows 20,673 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, HNSC, and ACC as cancer lineages where UBXN4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBXN4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBXN4 survival associations across molecular data types. UBXN4 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBXN4 RNA expression–survival associations across cancer types. High UBXN4 expression shows unfavorable associations in KIRP, LGG, UVM and ACC, but favorable associations in SKCM and KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for UBXN4 RNA expression.
This table summarizes UBXN4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for UBXN4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBXN4 shows lower tumor expression in KICH and THCA and higher tumor expression in HNSC, BLCA, STAD and BRCA. The HNSC box plot shows higher UBXN4 RNA expression in tumor versus normal tissue (log2 FC = +0.750, t-test p < 0.001).
This table shows molecular features associated with UBXN4 in patient tissues and cancer cell lines. In patient samples, UBXN4 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, UBXN4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
